MTOR and cardiac hypertrophy: In addition, the addition of the SIRT3 inhibitor nicotinamide increased the expression levels of p-Akt and p-mTOR, which were decreased by 2-APQC, suggesting that 2-APQC may inhibit the development of myocardial hypertrophy by activating the SIRT3-regulated Akt/mTOR signaling pathway (Fig. 3n).